Comparer des méthodes

	Analyse coût-efficacité (ACE)	Année de Vie en Bonne Santé Ajustée par l'Incapacité (AVISA)
Domaine	Économie de la santé	Économie de la santé
Famille	Process / pipeline	Process / pipeline
Année d'origine	1984	1990
Auteur d'origine	Drummond & Stoddart (Health Economics Research Group, McMaster University)	Christopher J. L. Murray and Alan D. Lopez (World Health Organization / World Bank)
Type	Method	Method
Source fondatrice	Gold, M. R., Siegel, J. E., Russell, L. B., & Weinstein, M. C. (Eds.). (1996). Cost-Effectiveness in Health and Medicine. New York: Oxford University Press.	Murray, C. J., Lopez, A. D., & Jamison, D. T. (1994). The Global Burden of Disease in 1990: Summary Results, Sensitivity Analysis, and Future Directions. In C. J. Murray & A. D. Lopez (Eds.), Global Burden of Disease and Injury. Cambridge: Harvard University Press.
Alias	CEA, ICER, Incremental Cost-Effectiveness Ratio	DALY, global disease burden metric, burden of disease
Apparentées	5	5
Résumé	Cost-effectiveness analysis compares the incremental cost per unit of health benefit gained by one intervention relative to a comparator (standard care or best alternative). Developed rigorously in the 1980s by Drummond, Stoddart, and colleagues, CEA is now the standard framework for technology appraisal globally. NICE, HAS, CADTH, and other health technology assessment bodies use CEA to decide which treatments warrant public funding and at what price.	A DALY quantifies disease burden as the sum of years of life lost to premature death and years lived with disability. Developed by the World Health Organization and World Bank in 1990 as part of the Global Burden of Disease (GBD) study, DALYs enable epidemiologists and public health planners to compare disease burden across populations, identify health priorities, and evaluate intervention impact. One DALY = one lost year of 'healthy' life; DALYs averted measure progress toward health goals.